NLS Pharmaceutics AG
NLSP · NASDAQ
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Market Cap | $11,614 | $116 | $329,270 | $762,727 |
| - Cash | $3,072 | $1,665 | $553 | $898 |
| + Debt | $0 | $0 | $1,714 | $1,634 |
| Enterprise Value | $8,542 | -$1,549 | $330,431 | $763,464 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | -$2 | $2 | -$6 | -$6 |
| % Margin | – | – | – | – |
| EBITDA | -$2,218 | -$1,585 | -$1,943 | -$4,258 |
| % Margin | – | – | – | – |
| Net Income | -$2,221 | $55 | -$2,036 | -$5 |
| % Margin | – | – | – | – |
| EPS Diluted | -10.5 | -9.9 | 0 | -1.4 |
| % Growth | -6.1% | – | 100% | – |
| Operating Cash Flow | -$2,074 | -$2,737 | -$1,530 | -$2 |
| Capital Expenditures | $0 | -$4 | $0 | $2,388 |
| Free Cash Flow | -$2,074 | -$2,741 | -$1,531 | -$2 |